Multivariable analysis of risk factors for outcome in the MInT study (823 young good-prognosis [aaIPI = 0, 1] patients)
| Risk factor . | EFS . | PFS . | OS . | |||
|---|---|---|---|---|---|---|
| HR [95% CI] without rituximab (n = 410) . | HR [95% CI] with rituximab (n = 413) . | HR [95% CI] without rituximab (n = 410) . | HR [95% CI] with rituximab (n = 413) . | HR [95% CI] without rituximab (n = 410) . | HR [95% CI] with rituximab (n = 413) . | |
| Elevated LDH | 1.9 [1.3-2.8] (P < .001) | 1.3 [0.8-2.1] (P = .342) | 1.8 [1.2-2.7] (P = .005) | 1.7 [1.0-3.1] (P = .073) | 2.1 [1.2-3.5] (P = .006) | 1.8 [0.8-3.7] (P = .151) |
| Stages III and IV | 1.7 [1.1-2.4] (P = .008) | 1.9 [1.2-3.1] (P = .007) | 1.6 [1.1-2.5] (P = .027) | 2.3 [1.3-4.1] (P = .004) | 0.9 [0.5-1.8] (P = .852) | 1.8 [0.8-3.9] (P = .162) |
| >1 Extralymphatic site | 1.5 [0.9-2.5] (P = .102) | 0.8 [0.4-1.7] (P = .547) | 1.3 [0.7-2.3] (P = .346) | 0.6 [0.2-1.6] (P = .302) | 2.5 [1.2-5.2] (P = .014) | 0.5 [0.1-2.2] (P = .391) |
| Male vs female | 1.3 [1.0-1.8] (P = .092) | 1.1 [0.7-1.7] (P = .660) | 1.1 [0.8-1.5] (P = .632) | 1.1 [0.7-1.7] (P = .799) | 1.3 [0.8-2.1] (P = .244) | 1.2 [0.6-2.4] (P = .535) |
| Risk factor . | EFS . | PFS . | OS . | |||
|---|---|---|---|---|---|---|
| HR [95% CI] without rituximab (n = 410) . | HR [95% CI] with rituximab (n = 413) . | HR [95% CI] without rituximab (n = 410) . | HR [95% CI] with rituximab (n = 413) . | HR [95% CI] without rituximab (n = 410) . | HR [95% CI] with rituximab (n = 413) . | |
| Elevated LDH | 1.9 [1.3-2.8] (P < .001) | 1.3 [0.8-2.1] (P = .342) | 1.8 [1.2-2.7] (P = .005) | 1.7 [1.0-3.1] (P = .073) | 2.1 [1.2-3.5] (P = .006) | 1.8 [0.8-3.7] (P = .151) |
| Stages III and IV | 1.7 [1.1-2.4] (P = .008) | 1.9 [1.2-3.1] (P = .007) | 1.6 [1.1-2.5] (P = .027) | 2.3 [1.3-4.1] (P = .004) | 0.9 [0.5-1.8] (P = .852) | 1.8 [0.8-3.9] (P = .162) |
| >1 Extralymphatic site | 1.5 [0.9-2.5] (P = .102) | 0.8 [0.4-1.7] (P = .547) | 1.3 [0.7-2.3] (P = .346) | 0.6 [0.2-1.6] (P = .302) | 2.5 [1.2-5.2] (P = .014) | 0.5 [0.1-2.2] (P = .391) |
| Male vs female | 1.3 [1.0-1.8] (P = .092) | 1.1 [0.7-1.7] (P = .660) | 1.1 [0.8-1.5] (P = .632) | 1.1 [0.7-1.7] (P = .799) | 1.3 [0.8-2.1] (P = .244) | 1.2 [0.6-2.4] (P = .535) |
Not adjusted for Eastern Cooperative Oncology Group Performance Status (ECOG) performance state because only 6 of the 823 patients had an ECOG >1.
CI, confidence interval; LDH, lactate dehydrogenase.